“…Thus, quality data for structural or procedural factors (e.g., waiting times, possibilities of comprehensive staging and preoperative risk stratification, the presence of interdisciplinary tumor conferences, expertise of the healthcare team, the number of intensive care unit staff, morbidity and mortality conferences) as well as further therapy outcome measures [e.g., toxicity criteria of multimodal treatment concepts, patient safety, hospital readmission rates, longterm survival, patient satisfaction and quality of life, in particular health-related quality of life (HRQOL) and quality-adjusted life years (QALYs)] are of equal relevance, although with lower levels of evidence in the literature [24]. Evidence-based benchmarking for the above parameters or a national expanded quality assurance program for a comprehensive evaluation of quality dimensions of hospitals treating patients with esophageal carcinoma, analogous, for example, to the nationwide registration of outcome data for the improvement in quality of care for rectal surgery-an initiative of the European Society for Surgical Oncology (ESSO)-is currently not in existence [65].…”